Actively Recruiting
Phase II Study of Disitamab Vedotin and Toripalimab for Advanced HER2-Positive Extramammary Paget Disease of the Scrotum
Led by Fujian Medical University Union Hospital · Updated on 2025-01-24
20
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
Sponsors
F
Fujian Medical University Union Hospital
Lead Sponsor
Z
Zhejiang Tumor Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are evaluating the combination of Disitamab Vedotin and Toripalimab to treat advanced HER2-positive extramammary Paget disease of the scrotum. This phase II clinical trial aims to determine if this combination reduces tumor size and delays disease progression, while also studying the safety and medical problems that may occur during treatment. Participants will receive intravenous infusions of Disitamab Vedotin at 2mgkg and Toripalimab at 3mgkg every 3 weeks. Treatment continues until the disease progresses, intolerable side effects occur, or other specified reasons arise. The study includes regular clinical tumor imaging and lesion measurements during treatment. Participants visit the clinic every 3 weeks for checkups and tests, including assessments of tumor response using RECIST criteria. The main outcome measured is the objective response rate every 6 weeks for up to 24 weeks. Secondary outcomes include progression-free survival and adverse events monitored over an average of 2 years. Follow-up continues until disease progression, withdrawal, loss to follow-up, or death.
CONDITIONS
Brief Title
A Study of RC48-ADC Combined With JS001 for Advanced Extramammary Paget Disease of the Scrotum
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Voluntarily sign the informed consent form and comply with the protocol requirements
- Age 18 years or older
- Confirmed diagnosis of scrotal extramammary Paget's disease with HER2 positive status
- ECOG performance status score of 0 to 1
- At least one measurable lesion on CT scan or skin lesion evaluable by WHO criteria
- Adequate organ function based on blood counts, liver, kidney, and coagulation tests
- Estimated life expectancy of at least 3 months
You will not qualify if you...
- History of immunodeficiency including HIV or organ transplantation
- Active autoimmune diseases requiring systemic treatment within 2 years prior to study
- Current systemic glucocorticoid or immunosuppressive therapy above specified doses
- History of active tuberculosis
- Uncontrollable or recurrent fluid drainage such as ascites or pleural effusion
- Major organ transplantation or major surgery within 28 days prior to study
- Chronic non-healing wounds or fractures
- Recent live attenuated vaccine administration or planned vaccination during the study
- Severe hypersensitivity to monoclonal antibodies or study drug components
- Participation in other clinical trials within 4 weeks prior to study
- History of severe allergies
- Risk of bleeding, coagulation dysfunction, or current thrombolytic therapy
- History of substance abuse or mental disorders affecting compliance
- Other serious diseases or conditions judged unsuitable by the investigator
Research Team
Y
Yiming Su, Doctor
R
Ru Chen, Doctor
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here